Want to see TSE:OILS full AI Analyst Report?
Nextleaf Solutions (OILS) AI Stock Analysis
Top Page
Nextleaf Solutions
(CNQX:OILS)
The score of 47 is primarily dragged down by weak technical indicators in a clear downtrend and unattractive valuation from ongoing losses, with mixed financial performance providing only partial support through cash flow gains.
Nextleaf Solutions (OILS) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 2.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 99.96K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 1.65
- Revenue Growth
- -18.30%
- EPS Growth
- -397.37%
- Country
- Canada
- Employees
- 26
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Nextleaf Solutions Business Overview & Revenue Model
Company Description
Nextleaf Solutions Ltd. operates as a cannabis extraction technology enterprise, pioneering and licensing advanced methods for the processing, refinement, and development of cannabinoid formulations throughout Canada. The company is actively involved...
How the Company Makes Money
Nextleaf Solutions makes money primarily through B2B cannabis processing and ingredient sales within regulated markets. Key revenue streams include: (1) selling bulk cannabinoid ingredients (e.g., refined cannabis oils/distillates) to licensed cannab...
Nextleaf Solutions Financial Statement Overview
Summary
Mixed results: weak income statement with declining revenue, negative margins and widening losses, offset by stable balance sheet with low debt and positive growing cash flows.
Income Statement
28NegativeBalance Sheet
68PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.90M | 11.26M | 12.48M | 8.18M | 4.41M | 3.38M |
| Gross Profit | -400.34K | 1.94M | 3.74M | 2.31M | 661.24K | -855.03K |
| EBITDA | -1.42M | 611.70K | -749.47K | 1.11M | -1.94M | -3.79M |
| Net Income | -1.92M | -162.94K | -1.44M | 223.33K | -3.49M | -5.39M |
Balance Sheet | ||||||
| Total Assets | 7.74M | 7.82M | 8.57M | 8.54M | 7.15M | 9.19M |
| Cash, Cash Equivalents and Short-Term Investments | 92.08K | 446.56K | 438.54K | 898.90K | 377.72K | 915.38K |
| Total Debt | 394.74K | 793.82K | 384.69K | 489.75K | 1.36M | 3.25M |
| Total Liabilities | 3.95M | 3.25M | 4.06M | 4.40M | 4.14M | 5.77M |
| Stockholders Equity | 3.78M | 4.57M | 4.50M | 4.13M | 3.02M | 3.43M |
Cash Flow | ||||||
| Free Cash Flow | 246.84K | 353.16K | -682.48K | 851.89K | -911.02K | -2.94M |
| Operating Cash Flow | 327.56K | 414.88K | -614.09K | 875.46K | -802.19K | -2.87M |
| Investing Cash Flow | -303.69K | -267.79K | -68.39K | -23.56K | -108.83K | -21.48K |
| Financing Cash Flow | -175.00K | -139.06K | 222.12K | -330.71K | 373.35K | 2.82M |
Nextleaf Solutions Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OILS, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 37.19 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OILS.
Nextleaf Solutions Peers Comparison
Overall Rating
TSE:LOVE77Outperform
TSE:OGI61Neutral
TSE:LABS49Neutral- TSE:OILS47Neutral
TSE:ATLE42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:LOVE | 77Outperform | CAD 198.55M | 17.69 | 9.45% | ― | 14.66% | -33.72% |
| TSE:OGI | 61Neutral | CAD 186.13M | 2.05 | 21.99% | ― | 38.14% | 2030.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| TSE:OILS | 47Neutral | CAD 3.40M | -1.75 | -43.92% | ― | -18.30% | -397.37% |
| TSE:ATLE | 42Neutral | CAD 41.96M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:OILS | Nextleaf Solutions | 0.02 | -0.04 | -66.67% | |
| TSE:ATLE | Willow Biosciences | 0.09 | -0.07 | -43.75% | |
| TSE:OGI | Organigram Global Inc. | 1.32 | -0.88 | -40.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -13.33% | |
| TSE:LOVE | Cannara Biotech, Inc. | 2.01 | 0.32 | 18.93% | |
| TSE:HASH | Simply Solventless Concentrates Ltd | 0.04 | -0.17 | -79.55% |
Nextleaf Solutions Corporate Events
Nextleaf Solutions Launches Strategic Review as CFO Sam Kassem Steps In as Interim CEO
NeutralInnovation-driven cannabis processor Nextleaf Solutions has announced a leadership change as Chief Executive Officer, President and director Emma Andrews steps down after eight years with the company. Andrews, who helped transform Nextleaf into a con...
Nextleaf Narrows Loss as Glacial Gold Strengthens Market Position
PositiveNextleaf Solutions reported fiscal third-quarter 2026 results showing modest sequential revenue growth and a sharply reduced net loss, aided by a product mix shift that cut excise taxes by nearly a third. Net revenue rose 5% to about $2.53 million, g...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026